I reported previously (see here) on Israel’s Intec Pharma which is developing treatments based on its innovative Accordion technology.  Intec’s COO Nadav Navon provided an update of Intec’s pipeline on ILTV.  Phase 3 trials have now commenced on Intec’s Parkinson’s … Continue reading →

Israel’s Intec has received a European patent for its Accordion oral treatment delivery system. Designed to improve efficacy and safety of any oral treatment, Accordion utilizes an efficient gastric retention and specific release mechanism. Intec itself has incorporated Accordion into … Continue reading →

Israeli biotech Intec has announced that its Accordion Levodopa treatment for Parkinson’s disease has met all its safety trial endpoints. Phase 3 trials on Parkinson’s sufferers can now commence. http://www.globes.co.il/en/article-intec-pharma-reports-safety-trial-success-1000946865

Israeli biotech Intec Pharma has reported successful final results of its Phase II clinical trial for the Zaleplon accordion pill, for the treatment of chronic insomnia. http://www.globes.co.il/serveen/globes/docview.asp?did=1000699916

Israel biotech Intec Pharma announced positive interim results in the Phase IIb clinical trial of its Levodopa accordion pill treatment for Parkinson’s disease. http://www.globes.co.il/serveen/globes/docview.asp?did=1000664721&fid=1725